Freeline Therapeutics

Freeline Therapeutics

Verified
Biopharmaceutical focused on the development and commercialisation of gene therapies for bleeding and other debilitating disorders

Launch date
Employees
Ownership
Market cap
$50m
Net debt
$32.6m
Firm valuation
$17m (Public information from Sep 2022)
Stevenage England (HQ)